Kiadis Pharma NV has appointed Robert Friesen as its chief scientific officer to lead the company’s cell therapy programmes enabling bone marrow transplantation. Dr Friesen joins Kiadis from Ablynx (now Sanofi SA) where he was also CSO. During his career he has been head of biologics research at Janssen BioTherapeutics and head of preclinical and clinical research at the Crucell Vaccine Institute, both of which are part of Johnson & Johnson Inc. Prior to this, he led preclinical and early clinical development at MorphoSys AG.
Dr Friesen holds a PhD in biochemistry from the University of Texas, US and did postdoctoral research at the University of Groningen in the Netherlands.
Kiadis announced the appointment on 4 February 2019.
Copyright 2019 Evernow Publishing Ltd